Neuroprotective and antioxidative effects of pioglitazone in brain tissue adjacent to the ischemic core are mediated by PI3K/Akt and Nrf2/ARE pathways

Yi Zhao 1 · Ulf Lützen 1 · Peter Gohlke 2 · Ping Jiang 3 · Thomas Herdegen 2 · Juraj Culman 4 ▪

Received: 1 October 2020 / Revised: 15 March 2021 / Accepted: 18 March 2021 / Published online: 16 April 2021 © The Author(s) 2021

Abstract
The present study elucidates the neuroprotective mechanisms of the PPARγ (peroxisome proliferator-activated receptor γ) agonist pioglitazone in survival of ischemic neurons following middle cerebral artery occlusion with reperfusion (MCAO). Intracerebroventricular infusion of pioglitazone over 5 days before and 24 or 48 h after MCAO alleviated neurological impairments, inhibited apoptosis 24 h, and activated the PI3K/Akt pathway along with increased phosphorylation of Akt (ser473) and GSK-3β (ser9) in the peri-infarct cortical areas 48 h after MCAO. In primary cortical neurons, pioglitazone suppressed the glutamate-induced release of lactate dehydrogenase by a PPARγ-dependent mechanism. This protective effect was reversed after co-treatment with PI3K and Akt inhibitors, LY294002 and SH-6, respectively. Pioglitazone enhanced the expression of the antioxidative transcription factor Nrf2 and its target gene protein, heme oxidase-1, in the peri-infarct area. Pioglitazone also increased activation of the antioxidant response element (ARE) in neuronal PC12 cells transfected with the pNQO1-rARE plasmid. We demonstrate in primary cortical neurons from Nrf2 knockout mice that the lack of Nrf2 completely abolished the neuroprotective effects of pioglitazone against oxidative and excitotoxic damage. Our results strongly suggest that the neuroprotective effects of PPARγ in peri-infarct brain tissues comprise the concomitant activation of the PI3K/Akt and Nrf2/ARE pathways.

Key messages
• Pioglitazone inhibits apoptosis in ischemic brain tissue.
• Pioglitazone acting on PPARγ activates PI3K/Akt pathway in ischemic brain tissue.
• Pioglitazone activates via Nrf2 the antioxidant defense pathway in injured neurons.
• Pioglitazone activates the antioxidant response element in neuronal PC12 cells.
• Pioglitazone fails to protect primary neurons lacking Nrf2 against oxidative damage.
• Activation of PPARγ supports the survival of viable neurons in peri-infarct regions.

Keywords Neuroprotection · Nrf2 · PPARγ · Pioglitazone · PI3K/Akt · Cerebral ischemia

Yi Zhao and Ulf Lützen contributed equally to this work.

Juraj Culman
juraj.culman@pharmakologie.uni-kiel.de

1 Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
2 Institute of Experimental and Clinical Pharmacology, University Hospital of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
3 University Clinic for Medical Radiation Physics, Medical Campus Pius-Hospital, Carl von Ossietzky University Oldenburg, 26121 Oldenburg, Germany
4 Institute of Experimental and Clinical Pharmacology, Faculty of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Arnold Heller Strasse 3, 24105 Kiel, Germany
Introduction

Tissue damage following cerebral ischemia depends on the reduction of the cerebral blood flow and on the duration of the ischemic insult \[1, 2\]. Application of the recombinant tissue plasminogen activator or mechanical thrombectomy is the only therapeutic interventions in stroke patients. An effective and well-tolerated neuroprotective therapy is still not available \[3\]. The data of a meta-analysis of experimental studies in rodents subjected to cerebral ischemia suggests that peroxisome proliferator-activated receptor γ (PPARγ) agonists improve the recovery from ischemic stroke \[4\]. Moreover, the preclinical trial has demonstrated that systemic treatment with pioglitazone of rats in the post-ischemic phase reduces infarct volume, alleviates neurological impairments, inhibits neuronal degeneration, and improves the outcome after stroke \[5\].

The PPARγ is constitutively expressed in the brain and cerebral ischemia robustly upregulates the PPARγ gene expression in neurons. The increased PPARγ expression in the peri-focal cortical areas is further enhanced by pioglitazone \[6, 7\]. PPARγ deficiency in neurons increased their susceptibility to ischemic brain damage \[8\]. These findings point to the unique function of cerebral PPARγ in ischemic brain tissue. A few studies focused on the effects of brain PPARγ activation on inflammatory reactions in ischemic brain tissue \[7, 9, 10\]. However, the exact role of cerebral PPARγ in the neuroprotection promoted by pioglitazone has not yet been extensively studied. Therefore, we investigated the effect of pioglitazone acting on cerebral PPARγ on activation of the canonical survival antioxidative phosphoinositide 3-kinase (PI3K)/Akt (protein kinase B)- and nuclear factor erythroid 2-related factor (Nrf2)/ARE pathways.

The role of PI3K, Akt, and Nrf2 in the pioglitazone-mediated neuroprotection against excitotoxicity and oxidative damage was studied in primary cortical neurons obtained from rats and Nrf2 knockout mice.

Materials and methods

Animals

Male Wistar rats 9–10 weeks old were obtained from Charles River (Sulzfeld, Germany). The rats were housed in the animal facility which meets the requirements of the European Directive 2010/63/EU on the Protection of Animals Used for Scientific Purposes. Zero- to 1-day neonatal Wistar rats or 0 to 1 neonatal C57BL/6 mice and Nrf2 knockout mice (B6.129X1-Nfe2l2tm1Ywk/J) were obtained from the same animal facility. All efforts have been made to minimize the suffering of the animals.

Surgical procedures (MCAO)

Osmotic minipumps (ALZET Model No. 2002, Charles River, Sulzfeld, Germany) filled with vehicle (50% dimethyl sulfoxide in physiological saline) or with pioglitazone (6 μmol/l, Takeda Pharma, Japan) were implanted 5 days before MCAO for 90 min with subsequent reperfusion \[13\]. In sham-operated rats, the occluding filament was not inserted. Regional cerebral blood flow (rCBF) was continuously monitored in each rat at one point (1 mm posterior to the bregma, 6 mm from the midline) on the surface of the hemisphere by laser-Doppler flowmetry (Periflux system 5000; PERIMED AB, Järfälla, Sweden). Body temperature was maintained at 37 °C with a heating pad. Chloral hydrate (400 mg/kg body weight) injected intraperitoneally was used as anesthetic for all surgical procedures. Rats in which no increase in rCBF was detected after pulling out the monofilament or rats suffering from intracerebral hemorrhage were excluded from the experimental protocols.

Neurological assessment

Neurological evaluations \[14\] were carried out by a blinded observer 24 and 48 h after MCAO as reported in detail previously \[5\] (sham-operated n=10, vehicle-treated n=12–14, and pioglitazone-treated n=12–14 at each time point). The minimum of the total neurological score is 3 and the maximum is 18 (see the Supplement).

Primary neuronal cell culture

Cortical neuronal cell cultures were prepared from the cerebral cortices from 0- to 1-day neonatal Wistar rats and from 0- to 1-
day neonatal C57BL/6 mice (controls) or Nrf2 knockout mice as described previously [9, 15] (see the Supplement).

**Experimental protocols**

Experiment 1: Western blot analysis of apoptosis markers and individual components of the PI3K/Akt pathway and Nrf2/HO-1

On day 6 after the implantation of osmotic minipumps, vehicle- and pioglitazone-treated rats were exposed to MCAO. The brains were removed from the skull 24 h (vehicle, n = 8; pioglitazone, n = 8, sham-operated, n = 8) or 48 h (vehicle, n = 8; pioglitazone, n = 8; sham-operated, n = 8) after MCAO, placed on the dorsal surface into a plastic brain matrix with a coronal slice orientation (World Precision Instruments, Sarasota, FL, USA), and cut into serial 1-mm-thick slices. Under a microscope, 1-mm-wide (determined from the infarct margin) pieces of frontoparietal cortical tissue were dissected from 3 consecutive coronal brain sections as described in detail previously [7]. The isolated proteins were used for Western blotting (see the Supplement).

Experiment 2: Immunofluorescence staining for phospho-Akt (p-Akt) (ser473), phospho-GSK-3β (p-GSK-3β) (ser9), PPARγ and Nrf2 in neurons localized at the border of the infarct region

Twenty-four or 48 h after MCAO, vehicle-treated (n=5) or pioglitazone-treated (n=5) rats were deeply anesthetized and intracardially perfused with ice-cold phosphate-buffered saline (pH 7.4) followed by 4% paraformaldehyde. Brain coronal sections (10 µm) were used for immunofluorescence staining [9] (see the Supplement).

Experiment 3: Effects of pioglitazone acting on PPARγ on glutamate-induced cytotoxicity in rat primary cortical neurons. The role of the PI3K and Akt

Seven days after plating, primary cortical neurons were treated with vehicle or pioglitazone (10 µM) in the presence or absence of the PPARγ antagonist GW 9662 (1 µM) added to the medium 30 min prior to pioglitazone. Thirty minutes after vehicle or pioglitazone treatment, cells were exposed to glutamate (100 µM). The concentrations of glutamate, pioglitazone, and GW 9662 were determined in previous experiments [15]. The assessment of cellular toxicity, carried out 24 h after glutamate treatment, was based on the quantification of lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells into the culture medium (Cytotoxicity Detection Kit, Roche Diagnostics) according to the manufacturer’s recommendations.

In the second set of experiments, primary cortical neurons were treated with vehicle or pioglitazone and exposed to glutamate (100 µM). One set of cells was pre-treated with LY294002 (10 µM), a non-selective, reversible inhibitor of PI3Kα/δ/β with IC50 of 0.5/0.57/0.97 µM, respectively. LY294002 is by far the most frequently used PI3K inhibitor in the medical biology research. Another set of cells was pre-treated with the selective Akt inhibitor SH-6 (5 µM). The inhibitors were added to the medium 30 min prior to pioglitazone. LDH release into the medium was determined 24 h after the treatment. The exposure of cells to pioglitazone, GW 9662, LY294002, and SH-6 alone did not induce any toxic effects (Fig. 4, and Table A in the Supplement). Each experiment was repeated 3 to 4 times with 3 samples in each group.

Experiment 4: Induction of the antioxidant response element (ARE)-mediated reporter activity by pioglitazone

Transfection of PC12 rat pheochromocytoma cells and the dual luciferase assay were carried out according to the method reported by Wruck et al. [16] (see the Supplement). Twenty-four hours after the transfection, the cells were stimulated with pioglitazone (1, 5, and 10 µM) with or without the PPARγ antagonist GW 9662 (1 µM). The activities of both luciferases were determined 24 h after stimulation with the PPARγ ligands. The luciferase activities were normalized to the Renilla reniformis luciferase activity of the internal control.

Experiment 5: Effects of pioglitazone on 6-hydroxydopamine (6-OHDA)- and glutamate-induced cytotoxicity in mouse primary cortical neurons from control and Nrf2 knockout mice

Seven days after plating, primary cortical neurons prepared from control, wild-type (C57BL/6) mice, and Nrf2 knockout mice were treated with vehicle or pioglitazone (10 µM) in the presence or absence of the PPARγ antagonist GW 9662 (1 µM). Thirty minutes after vehicle or pioglitazone treatment, neuronal cells were exposed to 6-OHDA (50 µM) or glutamate (100 µM) for 24 h. The neuronal cell death was assessed by measuring the LDH release to the medium. The immunofluorescence detection of β III-tubulin was carried out as described previously [15] (see the Supplement).

All experimental protocols were approved by the Governmental Committee for the Ethical Use of Experimental Animals in the German Federal State of Schleswig-Holstein and followed the Guidelines of the National Committee for the Protection of Animals Used for Scientific Purposes of the Federal Republic of Germany based on the Article 49 of EU Directive 2010/63/EU.
Chemicals and reagents

Pioglitazone obtained from Takeda Pharmaceuticals (Japan) was dissolved in DMSO and ultra-pure water (1:1) (stock solution). GW 9662, a selective PPAR\(\gamma\) antagonist (IC\(_{50}\) = 3.2 nM), was purchased from Cayman Chemicals Company and dissolved in DMSO. The vehicle solution consisted of DMSO and ultra-pure water. LY294002 (Cell Signaling Technology) and SH-6 (Enzo Life Sciences) were dissolved in DMSO (stock solution 10 mM) and diluted before the experiment with the culture medium. Glutamate (Sigma-Aldrich) was dissolved in the culture medium, and 6-OHDA (Sigma-Aldrich) in ascorbic acid (1 M) and diluted with the culture medium. All other chemicals and substances were purchased from Sigma-Aldrich or Merck.

Statistical analyses

The values are expressed as means ± SD. The distribution of the data was analyzed by Kolmogorov-Smirnov’s test and Bartlett’s test was used to test the homogeneity of variances. The statistical evaluation of changes in rCBF was carried out by two-way analysis of variance (ANOVA) with repeated measures. Two-tailed t-test was used to compare the data on the quantitative analysis of immunofluorescence images (p-Akt and p-GSK-3\(\beta\)). One-way ANOVA, followed by a post hoc Bonferroni test for pairwise comparisons, or the Kruskal-Wallis test was used to compare the Western blot analyses of apoptotic and neuroprotection parameters, expression of Nrf2 and HO-1, and the data on the LDH release from primary cortical neurons and the dual luciferase assay. Statistical significance was accepted at \(P < 0.05\).

Results

Regional cerebral blood flow, neurological outcome, and mortality

The rCBF during MCAO and reperfusion period were identical in the vehicle-treated and the pioglitazone-treated groups of rats (Fig. 1A). During MCAO, rCBF dropped by 75–80% and recovered to 75–100% of the baseline (B) in the reperfusion period. In sham-operated rats, rCBF decreased by 20–25% during the first 30 min of the common carotid artery occlusion and completely regained the baseline values at later time points (Fig. 1A).

Moderate reductions of rCBF in sham-operated rats had no impact on neurological outcome. Twenty-four hours after MCAO, neurological scores of symmetry of the movements of 4 limbs, forepaw outstretching and vibrissae touch (Fig. 1B, a), and the summation of all neurological scores of rats treated with pioglitazone were significantly better than those of
vehicle-treated rats (Fig. 1B, b). Forty-eight hours after MCAO, the pioglitazone-treated rats showed improved response to body proprioception (Fig. 1B, c). Previous findings have convincingly demonstrated that ICV infusion of pioglitazone reduces infarct volume and edema after ischemic stroke [7, 9, 10]. None of the sham-operated rats died during or after the surgery. Three rats treated with vehicle and 2 rats treated with pioglitazone died within 24 h after MCAO.

**Pioglitazone inhibits apoptotic cascade and promotes neuroprotection in the peri-infarct frontoparietal cortex**

In vehicle-treated rats, all apoptosis markers were considerably upregulated already 24 h after MCAO. Pioglitazone effectively reduced their induction but failed to completely abolish their expression which still remained higher than that detected in sham-operated animals (apoptopic protease-activating factor-1 (Apaf-1): $F_{2,16}=130.47$, $P<0.001$; cleaved (c)-caspase-9: $F_{2,16}=228.85$, $P<0.001$; cleaved (c)-caspase-3: $F_{2,16}=78.24$, $P<0.001$; PARP p85 fragment (c-PARP): $F_{2,17}=82.68$, $P<0.001$) (Fig. 2). Compared to sham-operated animals, all apoptosis markers were still significantly upregulated 48 h, but to a lesser extent than 24 h after MCAO. Pioglitazone failed to suppress the slightly increased expression of c-caspase-9 and c-caspase-3 (c-caspase-9: sham: 1.36 ±0.46, vehicle/MCAO: 2.14±0.51 a, pioglitazone/MCAO: 1.53±0.35; c-caspase-3: sham: 1.78±0.92, vehicle/MCAO: 4.92±1.33, pioglitazone/MCAO: 3.62±0.36; a$P<0.05$ and c$P<0.001$ vs sham-operated rats). However, pioglitazone downregulated the expression of Apaf-1 and c-PARP (Apaf-1: sham: 2.05±0.50, vehicle/MCAO: 3.70±0.49, pioglitazone/MCAO: 1.90±0.49 b; c-PARP: 2.01±0.25, vehicle/MCAO: 11.14±2.88, pioglitazone/MCAO: 7.28±0.88 c; $bP<0.01$ and $cP<0.001$, statistical comparison to sham-operated rats; $bP<0.001$ and $cP<0.001$, statistical comparison of the pioglitazone/MCAO group to the vehicle/MCAO group of rats). Survival of peri-infarct neurons which escaped apoptosis is driven by neuroprotective mechanisms. Twenty-four hours after MCAO, the tissue levels of all parameters of the PI3K/Akt cascade did not significantly differ among the experimental groups (Table 1). However, substantial changes in their expression were detected 48 h after ischemic damage (Fig. 3). The concentrations of PDK-1, total Akt, and Akt 3 decreased in ischemic tissue. ICV infusion of pioglitazone prevented this dramatic fall and returned the rate of their expression to values detected in sham-operated animals (PDK-1: $F_{2,17}=11.21$, $P<0.001$; Akt: $P<0.01$; Akt 3: $F_{2,17}=8.01$, $P<0.01$). Ischemic injury did not affect PI3K, p-Akt (thr308), p-Akt (ser473), and p-GSK-3β (ser9) levels in the peri-infarct tissue compared to sham-operated rats. Pioglitazone, however, considerably enhanced their expression (PI3K: $P<0.001$; p-Akt (thr308): $P<0.001$; p-Akt (ser473): $P<0.01$; p-GSK-3β (ser9): $P<0.001$) (Fig. 3).

**Double immunofluorescence staining of PPARγ on PI3K and Akt signalling was investigated in rat primary cortical neurons exposed to glutamate for 24 h.** As reported previously [15], increased LDH release induced by a 24-h exposure of neurons to glutamate was attenuated by prior treatment with pioglitazone. The selective PPARγ antagonist GW 9662 reversed the pioglitazone-induced inhibition of LDH release (Fig. 5A). In the second experiment, the PI3K inhibitor LY294002 or the Akt inhibitor SH-6 potentiated the effect of glutamate on LDH release (Fig. 5B).

**Western blot analysis of PI3K (phosphoinositide 3-kinase), PDK-1 (phosphoinositide-dependent kinase-1), Akt/PKB (protein kinase B), p-Akt (thr308) (phosphorylated Akt at threonine 308), p-Akt (ser473) (phosphorylated Akt at serine 473), Akt 3, and p-GSK-3β (ser9) (phosphorylated glycogen synthase kinase-3β at serine 9), in the frontoparietal cortex of sham-operated rats ($n=6–7$) and in the peri-infarct frontoparietal cortex isolated 24 h after MCAO in rats treated intracerebroventricularly with vehicle ($n=6–7$) or pioglitazone ($n=6–7$). Results (arbitrary units) are expressed as the means ± SD. Statistical comparisons revealed no significant differences in the expression of all key proteins of the PI3K/Akt signalling pathway among the experimental groups of rats (one-way ANOVA).

### Table 1  Effect of intracerebroventricular infusion of vehicle or pioglitazone on the PI3K/Akt signalling pathway in the frontoparietal cortex of sham-operated rats and in the peri-infarct frontoparietal cortex of rats 24 h after MCAO

| Parameter       | Sham  | Vehicle/MCAO | Pioglitazone/MCAO |
|-----------------|-------|--------------|-------------------|
| PI3K            | 1.08±0.28 | 0.66±0.56    | 1.03±0.80         |
| PDK-1           | 0.72±0.27 | 0.58±0.48    | 1.24±0.92         |
| Akt/PKB total   | 2.72±0.83 | 1.21±1.01    | 1.79±1.23         |
| p-Akt (thr308)  | 1.31±0.38 | 0.73±0.50    | 1.28±1.07         |
| p-Akt (ser473)  | 2.96±1.33 | 1.72±2.61    | 4.51±3.14         |
| Akt 3           | 1.66±0.31 | 0.98±0.67    | 1.43±1.20         |
| p-GSK-3β (ser9) | 0.93±1.28 | 1.51±1.20    | 1.95±1.12         |

**Pioglitazone augments the expression of Nrf2 and HO-1 in the peri-infarct frontoparietal cortex**

In addition to PI3K/Akt signalling, pioglitazone activated another neuroprotective pathway comprising the Nrf2 transcription factor and its target gene, HO-1. Pioglitazone induced a robust Nrf2 and HO-1 expression in the peri-infarct cortical tissue 48 h after the ischemic insult (Fig. 6A). In neurons
localized directly at the border of the ischemic core, pioglitazone considerably upregulated the expression of the Nrf2 already 24 h after MCAO (Fig. 6B).

**Induction of ARE-mediated reporter activity by pioglitazone**

PC12 cells were transfected with the constructed reporter pNQO1-rARE luciferase plasmid and luciferase activity was measured 24 h after incubation of cells with 1, 5, or 10 μM pioglitazone in the presence or absence of the PPARγ receptor antagonist GW 9662 (1 μM). Pioglitazone dose-dependently activated the luciferase gene expression. One micromolar pioglitazone had no effect (data not shown), but 5 and 10 μM pioglitazone activated the luciferase gene expression 1.5-fold (not significantly vs vehicle) and 2.2-fold ($P<0.001$ vs vehicle), respectively. Ten micromolar pioglitazone activated the luciferase gene expression more effectively than 5 μM
Pioglitazone requires Nrf2 to protect neurons against oxidative damage and excitotoxicity

The development of synaptic networks, characterized by the outgrowth of neurites and dendrites, is intimately associated with β III-tubulin (Fig. 7A, upper panel [a]) [17, 18]. Neurons from wild-type mice exposed to 6-OHDA or glutamate died or displayed signs of severe damage, characterized by the retraction and loss of neurites and dendrites. Pioglitazone promoted neurite outgrowth and formation of synaptic networks even in neurons exposed to 6-OHDA or glutamate and this effect was completely reversed by GW 9662, clearly indicating a PPAR γ-dependent mechanism (Fig. 7A, middle and lower panels [a]). The exposure of neurons to 6-OHDA or glutamate increased LDH release. Pioglitazone reduced the LDH release, and again, this rescue effect was completely abolished by GW 9662 (6-OHDA: \( F_{3,42}=366.05, P<0.001 \); glutamate: \( F_{3,32}=11.88, P<0.001 \)) (Fig. 7A [b, c]). Most importantly, pioglitazone failed to protect primary cortical neurons from Nrf2 knockout mice against oxidative and excitotoxic damage (Fig. 7B [d, e, f]).

Discussion

Previous findings have demonstrated that pioglitazone in the brain interacts with a number of pathophysiological events which evolve in ischemic brain tissue. In the early phase after ischemic stroke, pioglitazone reduces inflammatory reactions [7, 9, 10], which along with neuronal cell death substantially contribute to the expansion of ischemic injury. The present study demonstrates that pioglitazone acting on cerebral PPARγ exerts concerted actions resulting in inhibition of apoptosis and activation of neuroprotective cascades, including the Nrf2/ARE pathway in neurons adjacent to the ischemic core. The most prominent finding is the unique feature of pioglitazone which, besides the Nrf2 upregulation, also augments its binding to the ARE to increase the ARE activity.

The outcome after ischemic stroke depends on the interplay between apoptotic and anti-apoptotic events in the penumbra. Pioglitazone-infused ICV alleviated motor and sensory
deficits more effectively 24 h after MCAO and suppressed the apoptotic cascade, including the activation of the executioner caspase-3, an indicator of the irreversible progression of apoptosis. The underlying mechanisms are not fully understood. Anti-apoptotic effects of the PPARγ agonists 15d-PGJ2 and rosiglitazone, comprising the suppression of H₂O₂ generation and cytochrome-c release from mitochondria, have been demonstrated in an in vitro study [19].
The activation of the neuroprotective PI3K/Akt pathway supporting survival of peri-infarct neurons is essential for the improved recovery from ischemic stroke. Akt bound to the cell membrane via PIP3 synthesized by PI3K is activated by phosphorylation of threonine 308 and serine 473. The Akt-mediated phosphorylation promotes neuronal survival [11, 20–22]. GSK-3β acts as pro-apoptotic by activation of the pro-apoptotic factors, e.g., p53, and promotion of Nrf2 degradation [21, 22]. GSK-3β phosphorylation of serine 9 by Akt inactivates the kinase and prevents thus neuronal apoptosis [11]. Following cerebral ischemia, p-Akt is dephosphorylated and inactivated, a tendency also seen in the present study. A sustained phosphorylation of Akt was reported in the time period from 24 to 72 h after ischemic injury [21]. We report here that pioglitazone reversed the ischemia-induced down-regulation of Akt and increased p-Akt (thr308) and p-Akt (ser473), particularly 48 h after cerebral ischemia. A substantial upregulation of p-GSK-3β (ser9) was also detected at the same time point. The augmented expression of p-Akt (ser473) and p-GSK-3β (ser9) occurred in severely damaged neurons localized in close proximity to the ischemic core indicating that the upregulation of both kinases is prominent in neurons.

Fig. 7 Neuroprotective and neuroregenerative effects of pioglitazone (Pio) in mouse primary cortical neurons exposed to oxidative and excitotoxic damage induced by 6-hydroxydopamine (6-OHDA) and glutamate (Glu), respectively, are Nrf2-dependent. Control mice (A), left panels (a): Immunofluorescence staining against βIII-tubulin (green) shows that primary cortical neurons treated with vehicle developed neuritic and synaptic networks. Neurons exposed to 6-OHDA or Glu retained neurites and displayed serious neuronal damage. Pioglitazone restored the formation of synaptic networks in neurons exposed to 6-OHDA or Glu. The PPARγ antagonist, GW 9662 (GW), completely reversed the neuroprotective and neuroregenerative effects of pioglitazone. Middle panel (b) and right panel (c): Pioglitazone suppressed the 6-OHDA- or Glu-induced lactate dehydrogenase (LDH) release in primary cortical neurons of control mice and GW 9662 reversed this effect. Results are expressed as mean ± SD. **P<0.01, ***P<0.001, statistical comparison to neurons treated with vehicle; ††P<0.01 and †††P<0.001 statistical comparison to neurons treated with Glu and 6-OHDA, respectively; *P<0.05 and +++P<0.001, statistical comparison to Glu + pioglitazone-treated neurons and to 6-OHDA + pioglitazone-treated neurons, respectively, calculated by one-way ANOVA followed by a post hoc Bonferroni test. Nrf2 knockout mice (B), left panel (d): Pioglitazone failed to protect primary cortical neurons obtained from Nrf2 knockout mice against oxidative and excitotoxic damage induced by 6-OHDA or Glu. Middle panel (e) and right panel (f): Pioglitazone did not suppress the LDH release induced by 6-OHDA or Glu in these neurons. ***P<0.001, statistical comparison to vehicle-treated neurons, calculated by one-way ANOVA followed by a post hoc Bonferroni test.
in which the impact of ischemia is most pronounced. Furthermore, inhibitors of PI3K or p-Akt completely antagonized the pioglitazone-mediated neuroprotection in primary cortical neurons severely affected by neurotoxicity. All these findings convincingly demonstrate that interaction of pioglitazone with cerebral PPARγ considerably contributes to the activation of the PI3K/Akt pathway, which is considered a fundamental factor of neuronal survival after ischemic injury.

Oxidative stress is the hallmark of the response of brain tissue to ischemia. Excessive production of ROS leads to transcriptional activation of antioxidant genes initiated by binding of Nrf2 to the ARE [23]. Oxidative stress, Nrf2 phosphorylation, or GSK-3β inactivation promotes the translocation of Nrf2 into the nucleus and its binding to the ARE induces expression of antioxidant genes [24–27]. There are multiple interactions between the PPARγ and Nrf2 in terms of the regulation of the antioxidant gene expression. As the Nrf2 gene contains the peroxisome proliferator-activated receptor response elements (PPRE), activated PPARγ upregulates Nrf2, which, in turn, enhances the PPARγ expression. The localization of the PPRE and ARE in antioxidant genes allows their synergistic activation by both PPARγ and Nrf2 [28].

Intense Nrf2 immunoreactivity in ischemic neurons was already detected early, 24 h after cerebral ischemia (present data and [29]). In contrast, Western blotting revealed a substantial rise in Nrf2 concentration in the peri-infarct cortical tissue at 48 h. Immunofluorescence staining shows neurons severely affected by ischemia. On the other hand, Nrf2 quantification by Western blotting was carried out in a strip of peri-infarct brain tissue containing both severely damaged tissue and areas only moderately affected by blood flow restrictions. The induction of the Nrf2/ARE system in ischemic tissue was confirmed by the upregulation of HO-1. Apart from the Nrf2 upregulation, we demonstrate for the first time that pioglitazone also dose-dependently induces activation of the Nrf2/ARE system and thereby enhances the expression of a number of genes encoding for antioxidative enzymes indicating a robust activation of the antioxidant defense pathway in ischemic brain tissue.

Substantial evidence for the essential role of Nrf2 in the pioglitazone-mediated protection of neurons against oxidative stress or excitotoxicity is provided by experiments employing primary cortical neurons obtained from control and Nrf2 knockout mice. Pioglitazone prevented cell death induced by 6-OHDA or glutamate in cortical neurons from control mice by a PPARγ-dependent mechanism. The underlying mechanisms may involve the activation of antioxidant genes by the Nrf2/ARE system as pioglitazone failed to protect cortical neurons from Nrf2 knockout mice against oxidative and excitotoxic damage. This finding underlines the essential role of Nrf2 in the pioglitazone-triggered activation of the antioxidant defense pathway in injured neurons and prevention of neuronal death.

In conclusion, stimulation of PPARγ in ischemic brain tissue activates the neuroprotective and antioxidant defense pathways supporting the survival of viable neurons in the peri-infarct regions. The data substantiates the relevance of cerebral PPARγ for protection of neurons against ischemic damage which at last results in the improved recovery from cerebral ischemia. The results provide novel insight into the neuroprotective mechanisms linked to the activation of cerebral PPARγ and the rationale for conducting additional clinical trials investigating the use of pioglitazone in acute treatment of patients suffering from ischemic stroke [30].

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00109-021-02065-3.

Acknowledgements The authors wish to thank Dr. Kathryn Weise for the text editing and Mr. Jan Brdon for his excellent technical assistance.

Author contribution Yi Zhao made substantial contribution to the concept of the study, performed most of the experimental work, and collected and analyzed the data. Ulf Lützen made substantial contribution to the study conception and the interpretation of the data. Peter Gohlke made the design of experiments and revised critically the “Materials and methods” section. Ping Jiang revised critically the manuscript for intellectual content. Thomas Herdegen provided the Nrf2 knockout mice and carried out the final editing of the text. Juraj Culman conceived and designed the study, interpreted the data, supervised the study, and wrote the first draft of the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. The study was exclusively funded by the Institute of Experimental and Clinical Pharmacology and the Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein, Campus Kiel.

Declarations

Ethics approval The full name of the Ethic Committee, from which a written approval was obtained allowing to carry out the experiments, is stated in the “Materials and methods” section. The approval was given in writing.

Consent to participate Not applicable

Consent for publication Not applicable

Data transparency All authors confirm that all data and material support their published claims and comply with field standards.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

1. Dirmagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391–397
2. Kunz A, Dirmagl U, Mergenthaler P (2010) Acute pathophysiological processes after ischaemic and traumatic brain injury. Best Pract Res Clin Anaesthesiol 24:495–509
3. Powers WJ, Rabinstein AA, Ackerson T et al (2019) Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 50:e344–e418
4. White AT, Murphy AN (2010) Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. J Neurochem 115:845–853
5. Culman J, Nguyen-Ngoc M, Glatz T, Gohlke P, Herdegen T, Zhao Y (2012) Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischaemia: a preclinical stroke trial. Exp Neurol 238:243–253
6. Ou Z, Zhao X, Labiche LA, Strong R, Grotta JC, Herrmann O, Aronowski J (2006) Neuronal expression of Peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15d-prostaglandin J2- mediated protection of brain after experimental cerebral ischemia in rat. Brain Res 1096:196–203
7. Patzer A, Zhao Y, Stöck I, Gohlke P, Herdegen T, Culman J (2008) Peroxisome proliferator-activated receptors gamma (PPARgamma) differentially modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Eur J Neurosci 28:1786–1794
8. Zhao X, Strong R, Zhang J, Sun G, Tsen JZ, Cui Z, Grotta JC, Aronowski J (2009) Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci 29:6186–6195
9. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J (2006) Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 20:1162–1175
10. Glatz T, Stöck I, Nguyen-Ngoc M, Gohlke P, Herdegen T, Culman J, Zhao Y (2010) Peroxisome proliferator-activated receptors gamma and peroxisome proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. J Hypertens 28:1488–1497
11. Chong ZZ, Li F, Matek K (2005) Activating Akt and the brain’s resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol 20:299–315
12. Kang KW, Lee SJ, Kim SG (2005) Molecular mechanism of nrf2 activation by oxidative stress. Antioxid Redox Signal 7:1664–1673
13. Dai WJ, Funk A, Herdegen T, Unger T, Culman J (1999) Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 30:2391–2398
14. Garcia JH, Wagner S, Liu KF, Hu XJ (1995) Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 26:627–634
15. Zuhayra M, Zhao Y, von Forstner C, Henze E, Gohlke P, Culman J, Lützen U (2011) Activation of cerebral peroxisome proliferator-activated receptors γ (PPARγ) reduces neuronal damage in the substantia nigra after transient focal cerebral ischaemia in the rat. Neuropathol Appl Neurobiol 37:738–752
16. Wruck CJ, Götz ME, Herdegen T, Varoga D, Brandenburg LO, Pufe T (2008) Kavalactones protect neural cells against amyloid beta peptide-induced neurotoxicity via extracellular signal-regulated kinase 1/2-dependent nuclear factor erythroid 2-related factor 2 activation. Mol Pharmacol 73:1785–1795
17. Poulain FE, Sobel A (2010) The microtubule network and neuronal morphogenesis: dynamic and coordinated orchestration through multiple players. Mol Cell Neurosci 43:15–32
18. Gao J, Wals-Bass C, Ludueña RF (2010) The beta isoforms of tubulin in neuronal differentiation. Cytoskeleton (Hoboken) 67:431–441
19. Fong WH, Tsai HD, Chen YC, Wu JS, Lin TN (2010) Anti-apoptotic actions of PPAR-gamma against ischemic stroke. Mol Neurobiol 41:180–186
20. Manning BD, Toker A (2017) AKT/PI3K signaling: navigating the network. Cell 169:381–405
21. Zhao H, Saposky RM, Steinberg GK (2006) Phosphoinositide-3-kinase/akt survival signal pathways are implicated in neuronal survival after stroke. Mol Neurobiol 34:249–270
22. Rojo AI, Sagarr MR, Cuadrado A (2008) GSK-3beta down-regulates the transcription factor Nrf2 after antioxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 105:192–202
23. Niture SK, Kaspar JW, Shen J, Jaiswal AK (2010) Nrf2 signaling and cell survival. Toxicol Appl Pharmacol 244:37–42
24. Nguyen T, Nioi P, Pickett CB (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284:13291–13295
25. Alfieri A, Srivastava S, Siow RC, Modo M, Fraser PA, Mann GE (2011) Targeting the Nrf2-Keap1 antioxidant defence pathway for neurovascular protection in stroke. J Physiol 589:4125–4136
26. Ma Q (2013) Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53:401–426
27. Tonelli C, Chio IIC, Tuveson DA (2018) Transcriptional regulation by Nrf2. Antioxid Redox Signal 29:1727–1749
28. Cai W, Yang T, Liu H, Han L, Zhang K, Hu X, Zhang X, Yin JK, Gao Y, Bennett MVL, Leak RK, Chen J (2009) Peroxisome proliferator-activated receptor γ (PPARγ): a master gatekeeper in CNS injury and repair. Prog Neurobiol 86:165–203
29. Zhang R, Xu M, Wang Y, Xie F, Zhang G, Qin X (2017) Nrf2-a promising therapeutic target for defending against oxidative stress in stroke. Mol Neurobiol 54:6066–6071
30. Gomdzik M, Lenahan C, Tang J, Zhang JH (2020) Role of peroxisome proliferator-activated receptors in stroke prevention therapy – the best is yet to come? J Neurosci Res 98:2275–2289 Online ahead of print

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.